EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results/StudyNewron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia 16.02.2023 / 07:00 CET/CESTThe issuer is solely responsible.
Highly compelling, statistically significant, clinically meaningful improvement in assessments of symptoms of psychosis, disease severity and global evaluation at one year;increase in magnitude of
Hallucinations in the General Population Tied to Psychiatric Disorders medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
High Prevalence of Early-Onset Dementia in Schizophrenia Patients medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.